Search bioRxiv⌕ Search

Biology subjects

C, S.

Publications and source records attributed to C, S..

2 recordsLinked to original sources

Reprogrammed E. coli for secretion of thermophilic cellulase cocktail for seawater-compatible lignocellulosic bioprocessing

The development of efficient cellulase systems is crucial for sustainable lignocellulosic biorefining. In this study, we engineered Escherichia coli to co-express and secrete a thermophilic cellulase cocktail consisting of a Bacillus licheniformis processive endoglucanase (H1AD14), a Chaetomium thermophilum cellobiohydrolase (G0SAE6), and a glucose-tolerant engineered {beta}-glucosidase B8CYA8tm (V169C/E173L/I246A B8CYA8) from Halothermothrix orenii. Fusion with the AnsB secretion tag enabled extracellular yields of 0.2-0.4 g/L for each enzyme, bypassing costly purification while retaining activity. The secretion was confirmed via immunoblotting using anti-His antibody, and catalytic activity was validated through enzymatic assays. The absence of E. coli native periplasmic maltose-binding protein (detected with anti-MBP antibody) in the extracellular medium ruled out cell lysis, confirming protein secretion. Using the Golden Gate assembly, we constructed and systematically evaluated synergistic enzyme combinations for hydrolytic performance. By optimizing secretion conditions, including media, inducer concentration, and incubation temperature, the total yield of secreted enzyme cocktail increased from 0.31 g/L to 0.74 g/L. The secreted cocktail effectively hydrolysed diverse lignocellulosic substrates and exhibited 100 % activity in seawater, demonstrating potential for freshwater-independent biorefining. The work addresses key economic and environmental challenges in biomass conversion by integrating secretion engineering, thermostability, and seawater tolerance into a single scalable system.

bioengineering↗

Uttroside B, a US FDA-designated Orphan drug, mitigates thedevelopment of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ERK-mediated inhibition of SREBP-1 and STAT-3

Hepatocellular carcinoma (HCC) is a highly aggressive tumor with rapid propensity for extrahepatic metastasis, which critically limits the long-term clinical benefits of conventional chemotherapeutics and decreases the overall survival rate of patients. Our previous findings on the exceptional anti-HCC potential and pharmacological safety of uttroside B (Utt-B) have gained multiple international patents and the compound has been designated as an Orphan Drug against HCC by the US FDA. The current study substantiates the pharmacodynamics of Utt-B and is the first report to date on the anti-metastatic potential of the compound against HCC. Herein, we demonstrate the role of EGFR/ERK signaling axis and their downstream targets SREBP-1 and STAT-3, the key regulators of HCC development and the pulmonary metastasis, respectively, in orchestrating the anti-HCC and anti-metastatic potential of Utt-B. This is evidenced by the abrogation of the cytotoxic and pro-apoptotic effects of Utt-B upon pharmacological inhibition of this signaling axis. Orthotopic xenograft studies validated that Utt-B treatment restricted the development of tumors via the down-regulation of EGFR/ERK axis. Notably, Utt-B diminishes the migratory and invasive properties of liver cancer cells in vitro and impedes the pulmonary metastasis of HCC, in vivo. Taken together, the current findings attest to the exceptional therapeutic potential of Utt-B against primary and metastatic HCC and highlight its potential as a candidate drug to be evaluated in the clinics for the benefit of HCC patients having limited prognosis and therapeutic options.

cancer biology↗